MIF and CD74 as Emerging Biomarkers for Immune Checkpoint Blockade Therapy
Cancers · 04.05.2024 · 16 (9) · 1773
DOI: 10.3390/cancers16091773 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 04.05.2024. Verfasst von Rosalyn M Fey und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Oregon Health & Science University, Portland, OR 97239, USA. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 109 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, The American Cancer Society, The Department of Defense (DOD).
Abstract (Originalsprache)
Immune checkpoint blockade (ICB) therapy is used to treat a wide range of cancers; however, some patients are at risk of developing treatment resistance and/or immune-related adverse events (irAEs). Thus, there is a great need for the identification of reliable predictive biomarkers for response and toxicity. The cytokine MIF (macrophage migration inhibitory factor) and its cognate receptor CD74 are intimately connected with cancer progression and have previously been proposed as prognostic biomarkers for patient outcome in various cancers, including solid tumors such as malignant melanoma. Here, we assess their potential as predictive biomarkers for response to ICB therapy and irAE development. We provide a brief overview of their function and roles in the context of cancer and autoimmune disease. We also review the evidence showing that MIF and CD74 may be of use as predictive biomarkers of patient response to ICB therapy and irAE development. We also highlight that careful consideration is required when assessing the potential of serum MIF levels as a biomarker due to its reported circadian expression in human plasma. Finally, we suggest future directions for the establishment of MIF and CD74 as predictive biomarkers for ICB therapy and irAE development to guide further research in this field.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Dermatology, Oregon Health & Science University, Portland, OR 97239, USA.
- Yale Cancer Center, Yale University School of Medicine, New Haven, CT 06510, USA.
- Neuroimmunology Research, R&D-31, VA Portland Health Care System, Portland, OR 97239, USA.
- Department of Neurology, Oregon Health & Science University, Portland, OR 97239, USA.
- Department of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland, OR 97239, USA.
- Cancer Early Detection Advanced Research Center (CEDAR), Portland, OR 97239, USA.
ORCID-Profile: Rosalyn M Fey, Thuy T Tran, Rajan P Kulkarni
Förderung
- NCI NIH HHS
- The American Cancer Society
- The Department of Defense (DOD)
- OHSU Cancer Early Detection Advanced Research Center (CEDAR)
- ACED alliance award
- Kuni Foundation Discovery Grant
- NIH NINDS the National Institute of Allergy and Infectious Diseases award
- Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development Merit Review…
Zitieren
APA
Fey, R. M., Nichols, R. A., Tran, T. T., Vandenbark, A. A., & Kulkarni, R. P. (2024). MIF and CD74 as Emerging Biomarkers for Immune Checkpoint Blockade Therapy. Cancers, 16(9), 1773. https://doi.org/10.3390/cancers16091773
Vancouver
Fey RM, Nichols RA, Tran TT, Vandenbark AA, Kulkarni RP. MIF and CD74 as Emerging Biomarkers for Immune Checkpoint Blockade Therapy. Cancers. 2024;16(9):1773. doi:10.3390/cancers16091773
BibTeX
@article{Fey2024,
author = {Fey, Rosalyn M and Nichols, Rebecca A and Tran, Thuy T and Vandenbark, Arthur A and Kulkarni, Rajan P},
title = {MIF and CD74 as Emerging Biomarkers for Immune Checkpoint Blockade Therapy},
journal = {Cancers},
year = {2024},
volume = {16},
number = {9},
pages = {1773},
doi = {10.3390/cancers16091773}
}
EUVIMED